This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e50. Learning Objective-Upon completion of this activity, successful learners will be able to interpret the current state of the published literature related to health-related quality of life and economic burden in patients with eosinophilic esophagitis.
literature is lacking. Furthermore, little is known about the disease burden on patients, their caregivers, and the health care system. This study aimed to assess systematically the humanistic and economic burden of EoE, and to obtain evidence on how the disease affects HRQoL and expenditure for patients and caregivers. The cost effectiveness of current therapies was also assessed.
Methods
This systematic review was designed to identify published studies that include information on HRQoL and the economic burden of EoE, as well as the cost effectiveness of current treatments. Searches were conducted in Ovid on March 23, 2017, using comprehensive search strings that included a mixture of free text and Medical Subject Headings terms (Supplementary Table 1) , and using the following data sources: MEDLINE In-Process and Other NonIndexed Citations and Ovid MEDLINE, Embase, and Evidence-Based Medicine Reviews. Screening was performed according to the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 5 The Supplementary Methods section provides detailed information on study identification and selection.
Results

Identified Reports
The searches identified 676 articles, of which 567 were screened. After review of 102 potentially relevant publications, 13 studies related to HRQoL, 7 studies related to economic burden, and 2 cost-effectiveness articles were found to be relevant and included in this systematic review ( Figure 1 ). (the searches were designed to overlap by 1 month to allow for indexing lag within the databases). The identified references from both searches are combined in this PRISMA diagram. EBMR, EvidenceBased Medicine Reviews; HRQoL,
health-related quality of life; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Assessment of Health-Related Quality of Life in Patients With Eosinophilic Esophagitis
Study characteristics and the results of the 13 articles related to the impact of EoE on HRQoL are summarized in Table 1 .
The main outcome measure reported was HRQoL, measured by a validated instrument in all but 1 case (Table 1 and Supplementary Table 2) , [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] which used interviews and parent-and child-reported questionnaires. 18 Two of the instruments had been validated specifically for use in EoE: the Adult Eosinophilic Oesophagitis Quality of Life (EoO-QoL-A) questionnaire, and the validated Pediatric Quality of Life Inventory (PedsQL, Lyon, France) EoE module for pediatric patients and their caregivers. [15] [16] [17] Health-related quality of life in patients with eosinophilic esophagitis. Three studies compared HRQoL in patients with EoE with that in the general population and found that an EoE diagnosis was associated with significant impairments in aspects of HRQoL (Table 1  and Supplementary Table 2) . 7, 14, 17 A retrospective case-control study that measured HRQoL using the 12-item Short-Form Health Survey instrument found that after 15 years of follow-up evaluation, HRQoL in a group of primarily untreated children and young adults with "retrospective EoE" (based solely on eosinophil numbers on previously obtained biopsy specimens) was significantly worse than that in a group of healthy controls (median, 53 vs 57; P ¼ .002) and similar to that in patients with chronic esophagitis (median, 53 vs 53; P ¼ .91). 7 Similarly, a second study that used the 36-item ShortForm Health Survey (SF-36) General Health scale found that HRQoL was impaired significantly in patients with EoE, particularly young adults, compared with a national reference cohort containing a random and representative sample of the Dutch population (all age groups, 64.4 vs 70.9; P ¼ .024; age 18-25 years group, 50.1 vs 77.9; P ¼ .006).
14 In a prospective, cross-sectional, observational UK study using the SF-36 Health Survey and the EoO-QoL-A questionnaire to assess HRQoL, a significantly impaired mental, but not physical, QoL was reported in adults with EoE vs age-and sex-matched healthy individuals (52.5 vs 57.6; P ¼ .002). 17 Two studies reported the impact of EoE on parents/ caregivers and family functioning. 6, 18 Notably, the PedsQL Family Impact Module score correlated with age: the older the child, the better the overall Family Impact Module score (r ¼ 0.34; P ¼ .001), parent HRQoL score (r ¼ 0.28; P ¼ .0006), and family functioning score (r ¼ 0.35; P ¼ .0004). 6 A cross-sectional study that used interviews and child-and caregiver-reported questionnaires indicated that children with EoE (age, 2-17 y) often experienced frustration, negative moods, and anger resulting from the dietary or social restrictions associated with EoE. 18 Impact of treatment. Five studies evaluated the effect of treatment on HRQoL (Table 1 and   Supplementary Table 2) . [8] [9] [10] [11] 15 11 A recent prospective clinical trial showed that either swallowed fluticasone or a cow's milk elimination diet, each given in combination with a proton pump inhibitor (PPI), can be an effective therapy. 15 After 6 to 8 weeks of treatment, improvements relative to baseline in EoE-specific HRQoL were observed for both fluticasone combined with PPI (PedsQL EoE module total score, 75 vs 64; P ¼ .04) and a cow's milk elimination diet plus PPI (PedsQL EoE module total score, 82 vs 69; P ¼ .003). Nevertheless, improvements were significant only for the total score of the PedsQL EoE module, not for its subdomain scores. 15 The effect of dietary therapy on HRQoL appears dependent on which specific aspects of HRQoL are being measured: 1 study used the Patient Assessment of Upper Gastrointestinal Disorders-QoL instrument to show that the HRQoL score was significantly lower after restricted diets vs unrestricted diets (4.47 vs 4.87; P < .01) ( Table 1) , 8 whereas a second study used the SF-36 to indicate that the 6-food elimination diet (SFED) may improve the physical SF-36 scores of patients with EoE. 10 The dietary dimension of the Patient Assessment of Upper Gastrointestinal Disorders-QOL instrument evaluates concern, enjoyment, frustration, restriction, and avoidance in eating, whereas the SF-36 measures broader physical and mental health components.
Influence of symptoms. In a prospective trial using the EoO-QoL-A questionnaire, HRQoL was correlated strongly with symptom severity (r ¼ 0.610; P < .001) ( Table 1) . 12 Furthermore, symptom severity explained 18% to 35% of the variation in scores for each of the 5 HRQoL subscales (impact of diet/eating, social impact, emotional impact, disease anxiety, and swallowing anxiety). Variation in endoscopic and histologic findings explained 35% and 22%, respectively, of variation in the overall HRQoL scale scores with increased severities leading to poorer HRQoL. Similarly, a UK cross-sectional study reported a negative correlation between EoO-QoL-A scores and dysphagia scores (r ¼ -0.66; P < .001). 17 In support of this, a longitudinal study in children and adolescents with EoE using the PedsQL to measure HRQoL (EoO-QoL-A scores) correlated negatively with dysphagia (r ¼ -0.66, P < .001) and correlated positively with MCS (r ¼ 0.59, P < .001) Lower scores for general perception of health (P < .01), vitality (P < .001), and mental health (P < .01) in patients with EoE vs control MCS (EoE vs control): 52.5 vs 57.6 (P ¼ .002); no significant difference for PCS (57.4 vs 56.9, respectively) Dysphagia scores correlated negatively with PCS (r ¼ -0.38; P < .001) and MCS (r ¼ -0. HRQoL reported a negative correlation between the severity of EoE symptoms and HRQoL (P < .0001) over the course of 6 months. 6 Factors and disease-specific concerns. Two studies were designed to identify the clinical factors and diseasespecific concerns influencing HRQoL in adults with EoE (Table 1) . 13, 14 In 1 survey, patients with EoE (n ¼ 24) reported disease impacts on eating (87% of study participants), relief upon diagnosis (74%), concerns about dysphagia (67%), disease impact on social relationships (65%), concerns about available treatment (49%), and EoE as a new disease (26%). 13 A cross-sectional study found that disease duration and diagnostic delay were longer for patients with a lower SF-36 mental component summary score (MCS) than for patients with a higher MCS (P ¼ .029 and .027, respectively), whereas there was no significant association of current age, sex, concomitant atopic disease, age at onset of EoE symptoms, age at diagnosis, number of upper endoscopies, or HRQoL and the level of MCS.
14 Economic burden and cost effectiveness. Medical resource utilization costs for patients with EoE were significantly higher than those for healthy controls, indicating a considerable economic burden to the health care system as a result of the disease (Supplementary  Results and Supplementary Table 3) . Evidence relating to the cost effectiveness of EoE therapies suggests that SFED is a more cost-effective treatment option compared with topical corticosteroids (Supplementary Results and  Supplementary Table 4) .
Discussion
This systematic review found that EoE has a significant impact on HRQoL, resulting in disruption to and restrictions on daily life for patients, their caregivers, and, potentially, families. 6, 7, 14, 17, 18 Available treatments (eg, off-label topical corticosteroids, SFED, or cow's milk elimination diet) significantly improve the HRQoL of patients with EoE. [8] [9] [10] [11] 15 Furthermore, symptom severity appears to correlate strongly with impact on HRQoL. 6, 12 Medical resource utilization costs for patients with EoE are significantly higher than those for healthy controls. 19 Considerable knowledge exists about the nature of EoE and its symptoms. Frequent vomiting is common in babies, whereas toddlers/young children also may experience poor weight gain, and pain and difficulties with swallowing. Older children, adolescents, and adults may present with frequent vomiting, abdominal pain, dysphagia, or pain with swallowing. 1, 2 Key challenges in patients with EoE are assessment of EoE-specific symptoms, measurement of disease impact on daily wellbeing, and evaluation of the societal burden of disease. 1 The studies included in this systematic review provided strong evidence for impaired HRQoL and an increased economic burden for patients with this chronic disease. Results indicated that the effect of dietary therapy on HRQoL depends on which specific HRQoL aspects are being measured, 8, 10 suggesting that a restricted diet may impact HRQoL negatively when viewed from the perspective of meal enjoyment and limitations of daily activities, but that the impact becomes positive when symptomatology is considered. This finding was supported by a recent study showing that single-food elimination treatment is associated with significant symptomatic improvement. 15 These findings also indicate that some tools used for assessing HRQoL do not include all relevant domains for patients, leading to seemingly contradictory conclusions.
Costs of EoE include multiple esophagogastroduodenoscopies, medications (which are used off-label and may not be covered by health insurance), elemental diets, and food substitutions that often are more expensive than a regular diet and limit patient behavior. The economic burden of EoE is likely to continue to increase, given its increasing incidence and disease chronicity with the move toward shifting costs from the employer to the patient (particularly in the United States). Based on an analysis of the economic burden of all gastrointestinal illnesses, the costs attributable to EoE in the United States are striking and estimated to be of the same order of magnitude as hospital-related costs for acute appendicitis ($1.4 billion), gastrointestinal hemorrhage ($1.1 billion), Clostridium difficile infection ($1.1 billion), and inflammatory bowel disease ($1 billion). 20 The findings drawn from this systematic review are based on studies from the United States and Europe, and are limited in that HRQoL was measured mainly using instruments developed and validated in diseases other than EoE. Conclusions on the economic burden of EoE are based on US data only. Therefore, data relating to treatment costs and out-of-pocket expenses for patients with EoE in clinical practice are limited, and further studies are necessary to estimate more thoroughly the economic burden on health care systems, especially in places where cost controls are limiting endoscopy utilization. Moreover, only 2 studies providing relevant data on the cost effectiveness of EoE treatment were captured.
In conclusion, EoE is associated with a significant impact on HRQoL and increased medical resource utilization costs. Available treatments significantly improve the HRQoL of patients with EoE. Only 2 validated instruments have been developed to measure HRQoL in patients with EoE, and these instruments have not yet become widely used, which suggests a need for more and better disease-specific tools for assessing changes in HRQoL. Moreover, better ways to understand the impact of EoE on HRQoL and patient financial resources are needed, particularly given that EoE is a chronic disease, and manifestations may occur early in life. Complete assessment of the psychosocial impact should include other, less commonly quantified, issues such as employment prospects, lower levels of academic achievement, and failure to attain normal social development owing to disease-induced social restrictions.
Supplementary Methods
Identification of Studies
This systematic review was designed to identify published studies that included information on HRQoL and the economic burden of EoE, as well as the cost effectiveness of current treatment options.
Searches were conducted using comprehensive search strings that included a mixture of free text and Medical Subject Headings terms (Supplementary Table 1 ). The HRQoL searches combined terms relating to EoE with terms relating to quality of life, humanistic burden, health status, health utilities, and patientreported outcomes. The economic burden searches combined terms relating to EoE with terms relating to costs, hospital charges, resource utilization, and economic burden. The economic evaluation searches combined terms relating to EoE with terms relating to cost utility, cost effectiveness, cost minimization, and cost-benefit analysis.
Searches were conducted in Ovid on March 23, 2017, using the following data sources: MEDLINE In-Process and Other Non-Indexed Citations and Ovid MEDLINE (covering publications from 1946 to the present), Embase (covering publications from 1974 to the present), and Evidence-Based Medicine Reviews, comprising the Cochrane Database of Systematic Reviews, the American College of Physicians Journal Club archives, the Database of Abstracts of Reviews of Effectiveness, the Cochrane Central Register of Controlled Trials, the Cochrane Methodology Register, the Health Technology Assessments database, and the National Health Service Economic Evaluation Database. Searches were limited to English-language publications and studies in human beings.
Supplementary searches included a manual review of congress abstracts for conferences held in 2014 to 2016 by the following organizations: the American College of Gastroenterology; the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition; the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; the International Society for Pharmacoeconomics and Outcomes Research; and Digestive Disease Week. Additional publications were identified based on manual assessment of the titles of references listed in the articles selected for inclusion in this work and the systematic review publications identified in the searches described earlier.
Study Selection
Once publications had been identified, they were screened based on their title and abstract. The screening process was performed in accordance with the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
1 Abstracts were screened by 2 independent reviewers, and ambiguities were resolved by a third reviewer.
To be included in the final review, all publications identified had to meet specific inclusion/exclusion criteria. HRQoL searches excluded studies that did not provide sufficient information on the measures used to elicit HRQoL or the time points of HRQoL assessment, and studies that described the development or validation of an instrument itself. Publications that reported validated instruments designed to evaluate symptoms associated with EoE rather than measurement of HRQoL were outside the scope of this review. Economic burden studies had to include outcomes relating to direct costs, indirect costs, total costs, productivity loss, absenteeism and presenteeism, cost and burden to the caregiver, resource use, predictors of costs, or cost drivers. They were restricted further to studies on budget impact and cost/resource use analyses, and needed to state a clear objective of assessing costs or resource use. Economic evaluation studies had to include outcomes such as incremental cost-effectiveness ratios, life-years, qualityadjusted life-years, or cost drivers. Searches were not restricted by intervention or publication date.
Results
Assessment of the Economic Burden in Patients With Eosinophilic Esophagitis
Seven studies reported costs associated with EoE in children and adults in the United States (Supplementary Table 3) . [2] [3] [4] [5] [6] [7] [8] The most comprehensive of these used the LifeLink database to identify 8135 patients with EoE, and 32,540 sex-and age-matched controls. 2 Total costs summed over a period of 2 years (2009-2010) were higher for patients with EoE than for controls (median: EoE, US$6608; controls, US$2003; P < .001). This pattern was seen across all ages (range, 0-64 y) for allcause utilization of health care services, as well as for inpatient and outpatient costs. Medical resource utilization associated with the treatment of patients with EoE was higher than that associated with healthy controls, with annual direct costs of EoE in the United States ranging from US$503 million to US$1.36 billion, depending on the prevalence estimate. 2 Six further studies from the United States were identified suggesting increased medical resource utilization costs associated with patients with EoE compared with healthy individuals (Supplementary Table 3 ).
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Assessment of the Cost Effectiveness of Current Treatment Options for Patients With Eosinophilic Esophagitis
Evidence relating to the cost effectiveness of EoE therapies was limited; data came from 2 studies in adults with EoE, conducted in the United States (Supplementary Table 4) . 9, 10 A cost-utility analysis compared topical corticosteroids (fluticasone or budesonide) with SFED as a first-line therapy for adults with EoE over a 5-year time horizon from diagnosis. 9 Both treatments (SFED and topical corticosteroids) were similar in effectiveness; however, topical fluticasone (US$9262) and topical budesonide (US$21,609) were more expensive than SFED (US$5720 and US$7276, respectively). In a similar cost-effectiveness analysis, using a Markov model, the SFED was the most effective and least costly treatment option over 5 years, compared with fluticasone and budesonide, in a 30-year-old man with a new diagnosis of EoE. 10 In this analysis, costs were US$10,629 with SFED, compared with US$13,456 and US$27,100 for budesonide and fluticasone, respectively.
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